Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Pemigatinib selectively inhibits FGFR (fibroblast growth factor receptor) activity, a receptor that may contribute to the growth of leukemia cells. The genetic changes responsible for activating the growth of leukemia cells can be unique to each patient and can change during the course of the disease. Chemotherapy drugs, such as cytarabine and daunorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat w momencie wyrażenia zgody na uczestnictwo
- •Zdolność zrozumienia badania i chęć podpisania dokumentu świadomej zgody
- •Nowo rozpoznana ostra białaczka mieloidalna potwierdzona badaniem szpiku
- •Ryzyko pośrednie lub wysokie zgodnie z wytycznymi (nie ryzyko korzystne)
- •Brak mutacji FLT3 (określony typ genetyczny)
- •Sprawny stan ogólny pacjenta (stopień wydolności 0-2)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
OHSU Knight Cancer Institute
Portland, United States
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, United States
Trial contact
OHSU Knight Cancer Institute Clinical Trials Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.